Compare Abbott Laboratories (ABT) vs Flagstar Bank NA (FLG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Flagstar Bank NA — how do they compare? Abbott Laboratories trades at $109.36 (market cap $187.95B), while Flagstar Bank NA trades at $14.23 (market cap $5.82B). The key difference: Abbott Laboratories is far larger — about 32.3× Flagstar Bank NA's market cap, and Abbott Laboratories pays the higher dividend (2.32%). Which is the better fit depends on your goals.
| ABT | FLG | |
|---|---|---|
Market Cap | $187.95B | $5.82B |
Sector | Health | Financials |
52-Week High | $136.62 | $15.36 |
52-Week Low | $82.57 | $10.72 |
Enterprise Value | $214.96B | — |
Dividend Yield | 2.32% | 0.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.
Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.
Flagstar Bank (FLG) trades at $13.95, down 1.48% amid a bearish technical signal, though it remains profitable with a net income margin of 2.3% in 2026. Recent Q2 2026 earnings missed estimates, but the company announced a $250 million share repurchase program and continues dividend payments, reflecting confidence in its capital position. The stock trades below book value with a P/B of 0.76, offering a potential margin of safety.
The outlook is mixed: analyst consensus is bullish with a $16.85 price target, but risks include earnings volatility and competitive pressures. Upside hinges on execution of growth initiatives, while downside could stem from further earnings misses or economic headwinds affecting the banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →
